RayzeBio Snags $108M for Cancer Drug Efforts

San Diego-based RayzeBio, a pharmaceuticals company which says it is developing targeted radiopharmaceutical drugs for cancer, has raised $108M in its Series C funding. The company said it has now raised a total of $258M. The new funding was led by Venrock Healthcare Capital Partners and also include Perceptive Advisors, Vivo Capital, Acuta Capital Partners, Deerfield Management, and TCG X, plus existing investors venBio Partners, Versant Ventures, Samsara BioCapital, Redmile Group, Viking Global Investors, Cormorant Asset Management, OrbiMed, LifeSci Venture Partners, Logos Capital, Alexandria Venture Investments, and others. RayzeBio is developing targeted radioisotopes used for treating solid tumors. The company's president and CEO is Ken Song, M.D.